Compounds > acitretin
Page last updated: 2024-08-23

acitretin and plx4032

acitretin has been researched along with plx4032 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anforth, R; Blumetti, TC; Fernandez-Penas, P; Mohd Affandi, A1
Cranmer, L; Curiel-Lewandrowski, C; Erickson, CP; LaPresto, L; Morrison, L1
Anforth, R; Blumetti, TC; Clements, A; Fernandez-Peñas, P; Kefford, R; Long, GV1
Chon, SY; Geddes, ER; Sambrano, BL1
Fenchel, K; Sachse, MM; Wagner, G1
Plaza, JA; Ravikumar, S; Schieke, SM; Troy, JL; Yu, J1

Other Studies

6 other study(ies) available for acitretin and plx4032

ArticleYear
Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Acitretin; Aged; Carcinoma, Squamous Cell; Humans; Indoles; Keratolytic Agents; Male; Melanoma; Retinoids; Skin Neoplasms; Sulfonamides; Vemurafenib

2012
A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
    JAMA dermatology, 2013, Volume: 149, Issue:3

    Topics: Acitretin; Aged; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Indoles; Injections, Intralesional; Keratoacanthoma; Keratolytic Agents; Male; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib

2013
Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
    The British journal of dermatology, 2013, Volume: 169, Issue:6

    Topics: Acitretin; Aged; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Imidazoles; Indoles; Keratolytic Agents; Keratosis; Male; Melanoma; Middle Aged; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib

2013
Vemurafenib-related cutaneous side effects ameliorated by acitretin.
    Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:5

    Topics: Acitretin; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoprevention; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Keratolytic Agents; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides; Vemurafenib

2014
Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2014, Volume: 12, Issue:8

    Topics: Acitretin; Adult; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Eyelid Diseases; Female; Humans; Indoles; Keratoacanthoma; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 1; MAP Kinase Signaling System; Melanoma; Neoplasm Staging; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Signal Transduction; Sulfonamides; Vemurafenib

2014
Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
    The American Journal of dermatopathology, 2015, Volume: 37, Issue:5

    Topics: Acitretin; Aged; Biopsy; Cell Proliferation; Drug Eruptions; Eccrine Glands; Epithelial Cells; Humans; Indoles; Keratolytic Agents; Male; Melanoma; Metaplasia; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib

2015